Russell Basser

Dr Russell Basser has been the Senior Vice President of Research and Development since the formation of Seqirus in 2015. Seqirus is one of the largest influenza vaccine companies in the world and a major partner in the prevention and control of influenza globally.

Dr Basser led the clinical and regulatory programs that led to licensure of CSL’s influenza vaccine globally (Fluvax in Australia, Afluria in the US, Enzira in Europe), Australian approval of the pre- pandemic H5N1 bird flu vaccine, as well as the 2009 H1N1 swine flu pandemic program.